

Applying Strategies from Universal HIV Screening to Birth-Cohort HCV Screening:

Lessons Learned in an Urban Federally
Qualified Health Center (FQHC) Network

Conflict of Interest Disclosure

Melissa Kraus Schwarz

The following personal financial relationships with commercial interests relevant to this presentation existed during the past 12 months:

- Industry-sponsored grant: a Gilead FOCUS grant supports a portion of my salary.

Learning Objectives

- Understand the application of the TEST model to expand HIV and HCV screening.
- Identify barriers in HIV and HCV screening/treatment and strategies to overcome them.
- Discuss the use of data to inform quality improvement.
- Apply lessons learned from ACCESS' testing expansion initiatives to their own projects.

Presentation Overview

Presentation

- ACCESS background
- TEST Model
- HIV testing expansion
 - Implementation chronology
 - Lessons learned
- HCV testing expansion

Discussion


- Strategies to overcome barriers to testing expansion
- Using data for quality improvement

About ACCESS



- Network of 35 health centers serving Chicago and surrounding area
- Recognized Patient-Centered Medical Home offering comprehensive health care and wraparound services
- Serves predominantly low-income minority communities with high HIV prevalence
- Ryan White CARE Act-funded HIV services provider for more than 20 years

TEST Model



Testing Integrated in Clinical Workflows

- This is the desired endpoint
- Maximize sustainability
 - Employ regular staff rather than dedicated testers
 - Adapt workflows to make testing routine
 - Minimize stigma
- Supported by EHR Modifications, Systemic Policy Change, and Training/Feedback/QI

EHR Modifications – Best Practice Advisories


HIV

- Alert provider to need for screening
 - Annual for ages 13-64
 - One time age 65+
- SmartSet to simplify ordering
 - Document consent
 - Order test/link diagnosis
 - Add testing information to After Visit Summary

HCV

- Alert provider to need for screening
 - One time for patients born 1945-1965
 - People who inject drugs (PWID)


Number of HIV Tested Ordered by Day by BPA Status



Number of HIV Tested Ordered by Day by BPA Status

- Graph shows the impact of “Hard Stop” BPA implemented to mark the expansion of universal HIV screening
 - Hard stop required clinicians to address BPA immediately
 - Very unpopular and in place for very short time
 - Replaced by “Soft” BPA that did not have to be addressed during encounter
- Less disruptive Hard Stop activated for World AIDS Day
 - Hard stop required to be addressed before closing encounter
 - Less disruptive
- Hard Stop activated intermittently to maintain awareness but impact diminishing

HCV Screening by Month by Birth Cohort




HCV Screening by Month by Birth Cohort

- Graph shows impact of implementation of Birth Cohort BPA implemented August 2016
- Marked increase over a few months in number of patients born 1945-1965 screened for HCV
 - July 2016: 140
 - August 2016: 405
 - September 2016: 485
 - October 2016: 676
 - November 2016: **1,011**
- Soft BPA caused a less dramatic increase in screening than the Hard Stop HIV BPA but less disruptive and no pushback from clinicians

Systemic Policy Change

- BPAs most powerful tool but not sufficient without systemic policy change and leadership support
- Leadership support for lengthy process of integrating testing and linkage to care
 - 2012 HIV pilot at 7 sites
 - Universal HIV testing expansion with Hard Stop BPA June 2015
 - HCV Birth Cohort BPA August 2016
- Modification to general consent to treatment to include HIV screening
- Regional Medical Directors track HIV testing rates by health center, and provider testing rates included in quality metrics

HIV/HCV Testing Expansion Chronology



Lessons Learned from HIV Testing Expansion


- EHR modifications are a powerful tool to encourage routine screening
- Gain provider support to communicate the importance of testing within the context of primary care
- Changing testing rates at a population level takes sustained effort and attention over time
- Incorporate monitoring of testing rates into ongoing clinical quality measurement and improvement processes
- Assess and address barriers to testing and linkage to care and provide ongoing training and resources to address those barriers

Training/Feedback/QI

- Initial training for providers on universal HIV screening
 - Recommended by CDC
 - Some providers uncomfortable discussing risk behaviors
 - Information on internal HIV treatment resources and procedures for linkage to care
- Information on HIV BPA
- Monthly feedback for Regional Medical Directors on HIV and STI testing numbers and rates
- Monthly review of HIV and HCV testing metrics by ACCESS' Infectious Disease Quality Committee


Increasing Screening Rates a Long-Term Process

Patients Age 13+ by HIV Screening History



Increasing Screening Rates a Long-Term Process

Birth Cohort Patients by HCV Screening History



Increasing Screening Rates a Long-Term Process


Patients Age 13+ by HIV Screening History

- Upward trend lines for percent ever tested for HIV and percent “Up to Date” with recommended annual screening for ages 13-64 and onetime screening for age 65+
 - Ever Tested: 48% in January 2016 to **70%** in February 2019
 - Up to Date: 38% in January 2016 to **51%** in February 2019

Birth Cohort Patients by HCV Screening History

- Upward trend in percent of Birth Cohort ever tested for HCV
 - Started at 19% for birth cohort patients seen in January 2016
 - Reached **71%** (4,847) for birth cohort patients seen in February 2019


HCV Linkage Rates by Pilot Site



HCV Linkage Rates by Pilot Site

- At two initial pilot sites for linkage navigation 141 of 166 (85%) HCV RNA+ patients linked to care January 2016-February 2019
- At remaining sites 347 of 580 (60%) HCV RNA+ patients linked to care January 2016-February 2019
- Linkage Navigation expanded to 3 more sites in February 2018, linking 21 of 32 (66%) HCV RNA+ patients, about the same as the 64% linked at non-pilot sites during that time
- Overall upward trends for linking HCV RNA+ patients to appointment to initiate staging
- Linkage rates highest at two initial pilot sites with Linkage Navigators
- Linkage Navigators' reach expanded to 3 more sites in 2018
- Linkage rates declined overall in 2018



HCV Linkage by Provider Type





HCV Linkage by Provider Type

- Shows counts of patients testing HCV RNA+ each month who eventually linked with a primary care provider or specialist to initiate HCV staging for treatment
- Substantial fluctuation from month to month
- A number of PCPs completed Project ECHO HCV Treatment Training in 2017, and an increasing number of patients linked with PCP in 2017; that number decreased in 2018 as some trained providers left the organization
- Total **705** HCV RNA+ patients, January 2016 – February 2019
 - 305 Specialist (avg 8.0/month)
 - 148 to PCP (avg 5.1/month)
 - 252 Remained unlinked (avg 6.8/month)

Screening, Diagnosis, and Treatment Stepwise Cascade Percentages and Counts



Screening, Diagnosis, and Treatment Stepwise Cascade Percentages and Counts by Year



- HCV Ab+
- HCV RNA Tested
- HCV RNA+
- Linked to Care
- VL Zero after Linkage

Screening, Diagnosis and Treatment

- Two sets of graphs showing overall and year-by-year numbers and percentages for the cascade through screening, diagnosis, and treatment.
- Totals: **1,279** HCV Ab+, 1067 (83%) completed RNA test, of whom 706 (66%) were HCV RNA+. Of the RNA+ 453 (64%) linked to care, completing an appointment with an specifically trained PCP or Infectious Disease specialist to initiate staging for HCV. Of those positive, 154 (34% of linked) had one or more subsequent negative HCV RNA tests
- All numbers lowered in 2018 and in previous years reflecting progress in screening the birth cohort.

Discussion

- What are the barriers your organization faces in expanding HIV or HCV screening?
- What strategies can you think of to address them?
- What data do you feel are most valuable for monitoring your HIV or HCV testing efforts?

Contact Info

Melissa Kraus Schwarz

Evaluation Specialist

Access Community Health Network

Melissa.Schwarz@achn.net

312.526.2431